Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

40.17
+0.22000.55%
Post-market: 40.170.00000.00%19:30 EDT
Volume:765.29K
Turnover:30.70M
Market Cap:3.87B
PE:-20.54
High:41.48
Open:40.20
Low:39.58
Close:39.95
52wk High:42.68
52wk Low:23.23
Shares:96.27M
Float Shares:94.37M
Volume Ratio:1.08
T/O Rate:0.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9561
EPS(LYR):-1.2849
ROE:-16.22%
ROA:-11.54%
PB:3.23
PE(LYR):-31.26

Loading ...

Ideaya Biosciences, Servier announce topline results from OptimUM-02 trial

TIPRANKS
·
Apr 13

U.S. Stocks to Watch: Goldman Sachs, SanDisk, Exxon Mobil, Nvidia, Ideaya, and More

Tiger Newspress
·
Apr 13

Ideaya eye cancer drug meets main goal of mid-to-late-stage trial

Reuters
·
Apr 13

IDEAYA says darovasertib-crizotinib trial cuts progression risk 58% in metastatic uveal melanoma

Reuters
·
Apr 13

IDEAYA Biosciences Shares Gain 18% Premarket Ahead of Data Release for Its Experimental Cancer Drug

THOMSON REUTERS
·
Apr 13

IDEAYA Biosciences Inc - Trial Met Primary Endpoint Showing Statistically Significant Improvement in Median Pfs by Bicr

THOMSON REUTERS
·
Apr 13

IDEAYA Biosciences Inc - Nda Submission Planned for Second Half of 2026 to Support U.S. Accelerated Approval

THOMSON REUTERS
·
Apr 13

IDEAYA Biosciences and Servier Announce Positive Topline Results From Phase 2/3 Registrational Trial (Optimum-02) of Darovasertib in Combination With Crizotinib in First-Line Hla-a*02:01-Negative Metastatic Uveal Melanoma

THOMSON REUTERS
·
Apr 13

Why IDEAYA Biosciences Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

Benzinga_recent_news
·
Apr 13

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA) and Certara (CERT)

TIPRANKS
·
Apr 13

Ideaya Biosciences Shares Gain Ahead of Trial Results

Dow Jones
·
Apr 11

BRIEF-Ideaya Biosciences To Announce Topline Results From Phase 2/3 Optimum-02 Trial In Metastatic Uveal Melanoma On Monday, April 13, 2026

Reuters
·
Apr 11

IDEAYA to report topline OptimUM-02 darovasertib-crizotinib trial results April 13

Reuters
·
Apr 11

IDEAYA Biosciences to Announce Topline Results From Phase 2/3 Optimum-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026

THOMSON REUTERS
·
Apr 11

BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman

Reuters
·
Apr 10

Ideaya Biosciences Inc - Enters Clinical Collaboration Agreement With Astrazeneca On April 8, 2026 - SEC Filing

Reuters
·
Apr 09

IDEAYA, AstraZeneca partner to test IDE849 with Imfinzi in small cell lung cancer

Reuters
·
Apr 09

IDEAYA Biosciences Inc - Co to Sponsor Study; AstraZeneca to Supply Imfinzi - SEC Filing

THOMSON REUTERS
·
Apr 09

IDEAYA Biosciences Inc - Agreement to Evaluate Ide849 With Imfinzi in Extensive-Stage Small Cell Lung Cancer - SEC Filing

THOMSON REUTERS
·
Apr 09

IDEAYA Biosciences Inc - Advancing Global Phase 1 Trial for Ide849 in Dll3 Upregulated Solid Tumors - SEC Filing

THOMSON REUTERS
·
Apr 09